Psychotic Disorders

🧠 The Psychotic Spectrum: Decoding Reality's Disruption

You'll master the recognition, diagnosis, and management of psychotic disorders by understanding how dopamine dysregulation fractures reality perception and produces hallucinations, delusions, and disorganized thinking. This lesson builds your clinical precision through the spectrum from brief psychotic episodes to schizophrenia, equipping you with systematic assessment frameworks and evidence-based treatment algorithms. You'll learn to distinguish subtle diagnostic features, coordinate multi-system care, and deploy rapid decision tools that transform complex presentations into confident interventions that restore function and hope.

The psychotic spectrum encompasses multiple distinct conditions, each with unique presentations, prognoses, and treatment approaches. From brief psychotic episodes lasting days to weeks to chronic conditions requiring lifelong management, understanding these disorders requires mastering the interplay between neurobiology, genetics, environmental factors, and clinical presentation.

📌 Remember: PSYCHOTIC - Positive symptoms (hallucinations, delusions), Schizophrenia spectrum, Young adult onset, Cognitive impairment, Hereditary factors (40-80% heritability), Occupational dysfunction, Treatment resistance (30% of cases), Insight impairment, Chronic course potential

The diagnostic landscape includes seven major categories: schizophrenia, brief psychotic disorder, schizophreniform disorder, schizoaffective disorder, delusional disorder, substance-induced psychotic disorder, and psychotic disorder due to medical conditions. Each condition has specific duration criteria, functional impairment thresholds, and exclusion requirements that guide accurate diagnosis.

• Schizophrenia: Symptoms ≥6 months with significant functional decline
  • Prevalence: 0.3-0.7% globally
  • Peak onset: 15-35 years (males earlier by 3-5 years)
  • Positive symptoms: 90% experience hallucinations, 95% have delusions
    • Auditory hallucinations most common (60-90% of cases)
    • Command hallucinations in 18-58%, associated with higher violence risk
    • Persecutory delusions affect 80% of patients
• Brief Psychotic Disorder: 1 day to 1 month duration with full recovery
  • Prevalence: 0.05% in general population
  • 90% achieve complete remission within 30 days
  • Stress-related onset in 60% of cases
• Schizoaffective Disorder: Combined psychotic and mood symptoms
  • Prevalence: 0.3% globally, one-third the rate of schizophrenia
  • Better prognosis than schizophrenia, worse than mood disorders
  • 2 weeks of psychosis without mood symptoms required for diagnosis

⭐ Clinical Pearl: The "1-month rule" distinguishes brief psychotic disorder (≤1 month) from schizophreniform disorder (1-6 months) and schizophrenia (≥6 months). This temporal framework predicts prognosis: brief episodes have 90% recovery rates, while chronic presentations show 20-30% functional recovery.

Understanding the neurobiological substrate reveals why these conditions cluster together yet maintain distinct features. Dopaminergic hyperactivity in mesolimbic pathways underlies positive symptoms, while hypoactivity in mesocortical circuits produces negative symptoms and cognitive deficits. NMDA receptor hypofunction provides a unifying hypothesis explaining both dopaminergic abnormalities and the glutamate-GABA imbalance observed across the spectrum.

The genetic architecture shows polygenic inheritance with thousands of risk variants, each contributing small effect sizes (odds ratios 1.1-1.3). Copy number variants like 22q11.2 deletion carry higher risks (25-30% for psychosis) but remain rare. Environmental factors including prenatal infections (2-3x risk), urban birth (2.4x risk), and cannabis use (2-6x risk for high-THC products) interact with genetic vulnerability through epigenetic mechanisms.

Connect these foundational concepts through the neurobiological mechanisms that drive symptom expression and treatment response patterns.

---

⚡ The Dopamine Dysregulation Engine: Neurochemical Command Centers

The dopamine hypothesis remains central to understanding psychotic disorders, but modern neuroscience reveals a more complex multi-neurotransmitter network dysfunction. Four major dopaminergic pathways become dysregulated: the mesolimbic (hyperactive, causing positive symptoms), mesocortical (hypoactive, causing negative symptoms), nigrostriatal (affected by antipsychotics, causing movement disorders), and tuberoinfundibular (disrupted by medications, causing prolactin elevation).

📌 Remember: DOPAMINE - Delusions from mesolimbic hyperactivity, Occupital cortex visual processing disrupted, Prefrontal hypofunction (negative symptoms), Anhedonia from reward pathway dysfunction, Movement disorders from nigrostriatal blockade, Insight impairment from frontal dysfunction, NMDA hypofunction upstream, Endocrine effects (prolactin >25 ng/mL)

The NMDA receptor hypofunction hypothesis provides a unifying framework explaining both dopaminergic abnormalities and the broader neurochemical disruption. NMDA receptors on GABAergic interneurons normally provide tonic inhibition of glutamate release. When these receptors are hypoactive (40-60% reduction in schizophrenia), disinhibition occurs, leading to excessive glutamate release and downstream dopaminergic dysregulation.

• Mesolimbic Hyperactivity (Ventral Tegmental Area → Nucleus Accumbens)
  • 2-3x increased dopamine release during psychotic episodes
  • D2 receptor density increased by 10-15% in acute psychosis
  • Correlates with positive symptom severity (r = 0.6-0.8)
  • Amphetamine challenge produces 3-4x greater dopamine release
• Mesocortical Hypoactivity (VTA → Prefrontal Cortex)
  • 30-50% reduced dopamine in dorsolateral prefrontal cortex
  • Working memory deficits correlate with dopamine depletion
  • Cognitive symptoms emerge 2-5 years before psychosis
  • D1 receptor dysfunction impairs prefrontal-striatal circuits

⭐ Clinical Pearl: The "dopamine paradox" explains why antipsychotics can simultaneously improve positive symptoms (by blocking mesolimbic D2 receptors) while worsening negative symptoms (by further reducing mesocortical dopamine). Partial D2 agonists like aripiprazole address this by stabilizing rather than simply blocking dopamine transmission.

Glutamate system dysfunction extends beyond NMDA receptors to include AMPA and metabotropic glutamate receptors. Glutamate is the brain's primary excitatory neurotransmitter, comprising 80-90% of synaptic transmission. In psychotic disorders, glutamate-GABA balance shifts toward hyperexcitation, leading to excitotoxicity and progressive brain volume loss (1-2% annually in untreated schizophrenia).

💡 Master This: The glutamate-dopamine cascade explains why NMDA receptor enhancers (glycine, D-serine, glycine transport inhibitors) show promise for negative symptoms and cognitive deficits. By restoring NMDA function on GABAergic interneurons, these agents can normalize both glutamate disinhibition and downstream dopaminergic dysfunction.

Neuroinflammation emerges as a critical pathway linking genetic vulnerability, environmental stressors, and neurotransmitter dysfunction. Microglial activation increases 3-4x in first-episode psychosis, with elevated cytokines (IL-6, TNF-α, IL-1β) correlating with symptom severity. Complement system overactivation leads to excessive synaptic pruning, potentially explaining the progressive brain changes observed in chronic psychotic disorders.

Epigenetic mechanisms provide the interface between environmental factors and gene expression changes. DNA methylation patterns differ significantly in psychotic disorders, with hypermethylation of GABAergic gene promoters and hypomethylation of inflammatory genes. Histone modifications show dynamic changes during acute episodes, suggesting potential reversibility with appropriate interventions.

Connect these neurochemical insights through the clinical symptom patterns that emerge from specific circuit dysfunctions.

---

🎭 The Reality Distortion Matrix: Symptom Recognition Mastery

📌 Remember: POSITIVE - Paranoid delusions (80% of patients), Organized vs disorganized thinking, Sensory hallucinations (auditory 60-90%), Insight impairment (90% lack awareness), Thought broadcasting/insertion, Illusions vs hallucinations, Voices commenting/commanding, Excess dopamine mesolimbic

Positive symptoms represent "added" experiences not present in normal consciousness. Hallucinations occur in 60-90% of psychotic patients, with auditory hallucinations being most common (85% of cases). Command hallucinations occur in 18-58% and carry increased violence risk when combined with paranoid delusions. Visual hallucinations are less common (15-25%) and should prompt investigation for medical causes or substance use.

• Delusion Subtypes and Prevalence:
  • Persecutory: 80-85% of patients (most common)
  • Grandiose: 25-30% (higher in mania vs schizophrenia)
  • Somatic: 15-20% (body-related false beliefs)
  • Jealous: 10-15% (Othello syndrome, high violence risk)
  • Erotomanic: 5-10% (belief someone loves them)
  • Nihilistic: 5% (Cotard syndrome, severe depression)
• Formal Thought Disorder Patterns:
  • Circumstantiality: 30-40% (excessive detail, eventual goal)
  • Tangentiality: 25-35% (never reaches goal)
  • Loose associations: 40-60% (illogical connections)
  • Word salad: 5-10% (severe disorganization)

⭐ Clinical Pearl: "First-rank symptoms" (Schneider) include thought echo, voices arguing, thought insertion/withdrawal, thought broadcasting, delusional perception, and passivity phenomena. While historically considered pathognomonic for schizophrenia, they occur in 70% of schizophrenia but also 20% of bipolar disorder and 10% of severe depression.

Negative symptoms represent "absent" normal functions and predict poor functional outcomes. The "5 A's" framework organizes these symptoms: Alogia (poverty of speech), Affective flattening (reduced emotional expression), Avolition (lack of motivation), Anhedonia (inability to experience pleasure), and Attention deficits (concentration problems).

Cognitive symptoms often represent the most disabling aspect of psychotic disorders, affecting 85-95% of patients. Working memory deficits appear 2-5 years before psychosis onset and predict functional outcomes better than positive symptoms. Processing speed is reduced by 1-2 standard deviations, while executive function shows moderate to severe impairment in 70-80% of patients.

💡 Master This: The "hierarchy of symptoms" guides differential diagnosis: Organic causes (rule out first), Substance-induced (temporal relationship), Primary psychotic (schizophrenia spectrum), Mood disorders with psychosis (mood symptoms predominate), Personality disorders (chronic pattern). Timeline analysis is crucial: mood symptoms before psychosis suggest mood disorder, while psychosis without mood symptoms suggests schizophrenia spectrum.

Motor symptoms include both medication-induced and intrinsic movement abnormalities. Catatonia occurs in 10-15% of psychotic episodes, with higher rates in mood disorders (25-30%) than schizophrenia (5-10%). Neurological soft signs appear in 60-90% of patients and include sensory integration deficits, motor coordination problems, and primitive reflexes.

Insight impairment affects 90% of patients during acute episodes and 50-70% during stable periods. Anosognosia (lack of illness awareness) correlates with frontal lobe dysfunction and predicts medication non-adherence (40-60% of patients). Partial insight shows better treatment engagement and functional outcomes than complete denial.

Symptom severity scales provide standardized assessment: PANSS (Positive and Negative Syndrome Scale) ranges 30-210, with ≥95 indicating severe illness. BPRS (Brief Psychiatric Rating Scale) ranges 18-126, while SAPS/SANS separately assess positive and negative symptoms. CGI-S (Clinical Global Impression-Severity) provides overall severity rating from 1 (normal) to 7 (extremely ill).

Connect these symptom recognition patterns through the diagnostic frameworks that distinguish specific psychotic disorders.

---

🔍 The Diagnostic Precision Engine: Systematic Disorder Classification

The DSM-5 diagnostic hierarchy for psychotic disorders follows a systematic exclusion process: medical conditions (rule out first), substance-induced (temporal relationship), brief psychotic disorder (≤1 month), schizophreniform (1-6 months), schizophrenia (≥6 months), schizoaffective (mood + psychosis), and delusional disorder (circumscribed delusions). Each diagnosis requires specific duration criteria, functional impairment levels, and symptom constellation patterns.

📌 Remember: DURATION - Delusional disorder (≥1 month, minimal impairment), Under 1 month (brief psychotic), Range 1-6 months (schizophreniform), Above 6 months (schizophrenia), Two weeks psychosis without mood (schizoaffective), Induced by substances (temporal link), Organic causes (medical conditions), Need functional decline for schizophrenia

Schizophrenia requires ≥6 months of symptoms with significant functional decline in work, relationships, or self-care. Two or more of the following must be present for ≥1 month: delusions, hallucinations, disorganized speech, grossly disorganized/catatonic behavior, or negative symptoms. At least one symptom must be delusions, hallucinations, or disorganized speech.

• Functional Decline Criteria:
  • Work/Education: Major deterioration from previous level
  • Interpersonal Relations: Marked impairment in social functioning
  • Self-Care: Significant decline in hygiene, nutrition, housing
  • Quantitative Measures: GAF <50 or PSP <50 indicates significant impairment
• Exclusion Requirements:
  • Schizoaffective/Mood Disorders: Mood episodes brief relative to psychosis
  • Substance Use: Not attributable to physiological effects
  • Medical Conditions: Not due to another medical condition
  • Autism Spectrum: If ASD present, prominent delusions/hallucinations required

⭐ Clinical Pearl: The "6-month rule" for schizophrenia reflects the critical threshold where spontaneous recovery becomes unlikely (<10%) without treatment. Schizophreniform disorder (1-6 months) has 60-70% recovery rates, emphasizing the importance of early intervention during the critical period.

Schizoaffective Disorder requires concurrent mood episodes and psychotic symptoms, with ≥2 weeks of psychosis without prominent mood symptoms. This "2-week rule" distinguishes it from mood disorders with psychotic features, where psychosis occurs only during mood episodes. Bipolar type (manic/mixed episodes) has better prognosis than depressive type (major depression only).

Brief Psychotic Disorder requires sudden onset of ≥1 positive symptom lasting ≥1 day but <1 month, with eventual return to normal functioning. Three specifiers exist: with marked stressor (reactive), without marked stressor, and with postpartum onset (within 4 weeks of delivery). Postpartum psychosis affects 1-2 per 1000 deliveries and carries high risk for infanticide (4%) and maternal suicide (5%).

💡 Master This: Temporal analysis is crucial for accurate diagnosis. Create a timeline documenting: symptom onset, mood episode timing, substance use periods, medical conditions, and functional changes. The sequence and duration of symptoms, not just their presence, determines the correct diagnosis and predicts treatment response and prognosis.

Substance-Induced Psychotic Disorder requires temporal relationship between substance use and symptom onset, with symptoms exceeding what would be expected from intoxication or withdrawal. Cannabis (2-6x risk), amphetamines (10-15x risk), and alcohol withdrawal are common causes. Symptoms typically resolve within days to weeks of substance discontinuation.

Psychotic Disorder Due to Medical Condition results from direct physiological effects of a medical condition. Common causes include autoimmune encephalitis (anti-NMDA receptor), temporal lobe epilepsy, brain tumors, neurodegenerative diseases, and endocrine disorders. Onset is often acute with neurological signs and cognitive impairment.

Differential diagnosis challenges include distinguishing first-episode psychosis from bipolar disorder (25% misdiagnosed initially), autism spectrum disorders with psychotic features, severe personality disorders with transient psychosis, and cultural/religious experiences that may appear psychotic to unfamiliar clinicians.

Connect these diagnostic frameworks through the evidence-based treatment algorithms that optimize outcomes for each specific disorder.

---

⚖️ The Treatment Algorithm Matrix: Evidence-Based Intervention Strategies

First-line treatment algorithms vary significantly across psychotic disorders, with antipsychotic medications forming the cornerstone for most conditions. Response rates range from 60-80% for first-episode psychosis to 30-50% for treatment-resistant cases. Time to response typically requires 2-6 weeks for positive symptoms and 6-12 weeks for negative symptoms, with full benefits emerging over 3-6 months.

📌 Remember: TREATMENT - Time to response (2-6 weeks positive, 6-12 weeks negative), Response rates (60-80% first episode), Early intervention critical (DUP <6 months), Antipsychotic choice (FGA vs SGA), Treatment resistance (30% of cases), Monitoring required (metabolic, neurological), Engagement strategies, Non-adherence (40-60%), Targeted therapy (clozapine for TRS)

Second-generation antipsychotics (SGAs) are first-line for most psychotic disorders due to lower extrapyramidal side effects (5-15% vs 30-50% for FGAs) and potential efficacy for negative symptoms. Metabolic monitoring is crucial, with weight gain (7-15 kg average), diabetes risk (2-3x increased), and dyslipidemia (40-60% of patients) being major concerns.

• Antipsychotic Selection Criteria:
  • Efficacy: No significant differences between SGAs for positive symptoms
  • Side Effect Profile: Individual variation in tolerability
  • Patient Factors: Age, comorbidities, previous responses
  • Formulation: Oral vs long-acting injectable (LAI)
• Dosing Strategies:
  • Start Low: 25-50% of target dose to assess tolerance
  • Titrate Slowly: Weekly increases to minimize side effects
  • Therapeutic Range: D2 occupancy 65-80% for efficacy
  • Maximum Benefit: 4-6 weeks at therapeutic dose

⭐ Clinical Pearl: Duration of untreated psychosis (DUP) is the strongest predictor of treatment response and long-term outcomes. DUP >6 months is associated with poorer response (40% vs 70%), greater brain volume loss, and worse functional outcomes. Early intervention services can reduce DUP from 12-24 months to 3-6 months.

Treatment-resistant schizophrenia (TRS) affects 30% of patients and is defined as failure to respond to ≥2 adequate trials of different antipsychotics for ≥6 weeks each at therapeutic doses. Clozapine remains the gold standard for TRS, with response rates of 30-60% compared to <5% for other antipsychotics in this population.

Long-acting injectable (LAI) antipsychotics address medication non-adherence, which affects 40-60% of patients and increases relapse risk by 3-5x. LAI formulations reduce relapse rates by 20-30% compared to oral medications, with monthly and quarterly options available. Paliperidone palmitate and aripiprazole are first-line LAI options due to favorable side effect profiles.

💡 Master This: Personalized treatment selection requires integrating clinical factors (symptom profile, comorbidities), patient preferences (side effect tolerance, route of administration), social factors (family support, adherence history), and biological markers (genetic testing for CYP2D6 metabolism, HLA-B*5701 for clozapine). Shared decision-making improves treatment engagement and long-term outcomes.

Monitoring protocols are disorder-specific and medication-dependent. Baseline assessments include metabolic panel, lipid profile, HbA1c, prolactin, CBC, and ECG. Follow-up monitoring occurs at 1, 3, 6, and 12 months, then annually. Clozapine requires weekly CBC for 18 weeks, then biweekly for 6 months, then monthly due to agranulocytosis risk (0.8%).

Augmentation strategies for partial response include antidepressants for negative symptoms (30-40% response), mood stabilizers for affective symptoms, and cognitive enhancers for cognitive deficits. Combination antipsychotics show limited evidence except for clozapine augmentation with aripiprazole or amisulpride.

Connect these treatment algorithms through the integrated care models that optimize long-term outcomes and functional recovery.

---

🔗 The Recovery Integration Network: Multi-System Care Coordination

Integrated care models demonstrate superior outcomes compared to fragmented services, with coordinated specialty care (CSC) for first-episode psychosis showing 40-50% better functional outcomes and 20-30% lower hospitalization rates. Critical components include rapid access (≤2 weeks), low caseloads (1:10-15 ratio), team-based care, and family involvement in ≥80% of cases.

📌 Remember: RECOVERY - Rapid access (≤2 weeks), Early intervention critical, Coordinated specialty care, Outcomes improved (40-50% better function), Vocational rehabilitation, Engagement strategies, Relapse prevention, Young adult focus (15-35 years)

Recovery-oriented care shifts focus from symptom management to functional restoration and quality of life. Personal recovery emphasizes hope, identity, meaning, and responsibility, while clinical recovery focuses on symptom reduction and functional improvement. Measurement-based care using standardized assessments improves outcomes by 25-35% compared to routine care.

• Core Recovery Principles:
  • Person-Centered: Individual goals and preferences guide treatment
  • Strengths-Based: Build on existing capabilities and resources
  • Trauma-Informed: Address underlying trauma in 60-90% of patients
  • Cultural Competence: Adapt interventions to cultural context
• Functional Outcome Domains:
  • Independent Living: Housing stability (70% achieve stable housing)
  • Employment/Education: Vocational participation (40-60% return to work/school)
  • Social Relationships: Social network size and quality
  • Community Integration: Participation in community activities

Cognitive remediation addresses the cognitive deficits that predict functional outcomes more strongly than positive symptoms. Computer-based training programs show moderate effect sizes (0.4-0.6) for working memory, attention, and processing speed. Combined approaches integrating cognitive training with vocational rehabilitation demonstrate synergistic effects with 60-70% employment rates.

Supported employment using the Individual Placement and Support (IPS) model achieves competitive employment in 40-60% of participants compared to 10-20% in traditional vocational services. Key principles include zero exclusion, rapid job search, competitive employment focus, integration with mental health treatment, and ongoing support.

⭐ Clinical Pearl: Peer support specialists with lived experience of psychotic disorders improve engagement (80% vs 60%), medication adherence (70% vs 50%), and hope/empowerment scores. Peer-delivered services are cost-effective, with $3-4 saved for every $1 invested through reduced hospitalizations and emergency services.

Family interventions are evidence-based treatments that reduce relapse rates by 20-30% and improve family functioning. Psychoeducation increases knowledge about illness and treatment, while communication training reduces expressed emotion (criticism, hostility, emotional over-involvement) that predicts relapse (65% vs 35% in low-EE families).

Trauma-informed care is essential given that 60-90% of individuals with psychotic disorders have trauma histories. Trauma-focused therapy adapted for psychosis shows safety and efficacy for PTSD symptoms without exacerbating psychotic symptoms. Integrated treatment addressing both trauma and psychosis improves overall outcomes.

💡 Master This: Staging models guide intervention intensity based on illness phase: Stage 0 (at-risk mental state), Stage 1a (first episode), Stage 1b (early recovery), Stage 2 (recurrent episodes), Stage 3 (treatment resistance), Stage 4 (severe persistent illness). Early stages require intensive but time-limited interventions, while later stages need long-term maintenance and rehabilitation focus.

Cultural adaptations are crucial for diverse populations, with culturally adapted interventions showing 20-30% better engagement and outcomes. Considerations include explanatory models of illness, family involvement patterns, religious/spiritual beliefs, language preferences, and community resources. Community health workers can bridge cultural gaps and improve access to care.

Quality indicators for psychotic disorder care include time to treatment (≤2 weeks), medication adherence (≥80%), family involvement (≥60%), employment/education participation (≥40%), housing stability (≥80%), and hospitalization rates (≤20% annually). Continuous quality improvement using these metrics drives better outcomes and system performance.

Connect these integrated care principles through the rapid mastery frameworks that enable clinical excellence in psychotic disorder management.

---

🎯 The Clinical Mastery Arsenal: Rapid Assessment and Decision Tools

Rapid assessment protocols enable efficient evaluation while ensuring comprehensive coverage of critical domains. The "PSYCHOSIS" framework provides systematic assessment: Positive symptoms, Substance use, Young adult onset, Cognitive function, History (family/personal), Organic causes, Suicide risk, Insight level, Social functioning. Complete evaluation requires 60-90 minutes initially, with follow-up assessments in 15-30 minutes.

📌 Remember: RAPID - Risk assessment (suicide 10% lifetime), Assessment tools (PANSS, BPRS), Pharmacotherapy selection, Insight evaluation (90% impaired acutely), Differential diagnosis (medical, substance, psychiatric)

Essential Clinical Thresholds for immediate memorization:

• Suicide Risk: 10% lifetime rate in schizophrenia, highest in first 5 years
• Treatment Response: 2-6 weeks for positive symptoms, 6-12 weeks for negative
• Relapse Prevention: LAI reduces relapse by 20-30% vs oral medications
• Functional Recovery: 20-30% achieve good outcomes in schizophrenia
• Treatment Resistance: 30% of patients, requires clozapine consideration
• Medication Adherence: 40-60% non-adherent, 3-5x higher relapse risk
• Duration Thresholds: <1 month (brief), 1-6 months (schizophreniform), ≥6 months (schizophrenia)

Diagnostic Decision Tree for rapid differential diagnosis:

High-Yield Clinical Pearls for immediate application:

⭐ Suicide Risk Factors: Command hallucinations + paranoid delusions = highest risk. Depression in 50% of schizophrenia patients. First 5 years after diagnosis carry greatest risk. Assess directly: "Are you having thoughts of hurting yourself?"

⭐ Medication Selection: No SGA superior for positive symptoms. Choose based on side effect profile: Aripiprazole (minimal weight gain), Quetiapine (sedating), Olanzapine (efficacious but metabolic risk). Start low, go slow, monitor closely.

⭐ Treatment Resistance: Two failed trials of different antipsychotics for ≥6 weeks each at therapeutic doses. Clozapine is gold standard with 30-60% response in TRS. Weekly CBC monitoring required.

Rapid Screening Tools for clinical efficiency:

• Safety: Agitation, violence risk, self-harm potential
• Medical: Vital signs, neurological exam, substance intoxication
• Capacity: Decision-making ability, insight level, treatment consent
• Collateral: Family history, previous episodes, medication response
• Disposition: Inpatient vs outpatient, voluntary vs involuntary

💡 Master This: "The 3 C's" of psychotic disorder management: Clarify the diagnosis through systematic assessment, Choose evidence-based treatments matching patient factors, Coordinate comprehensive care addressing medical, psychological, and social needs. Success requires persistence, patience, and partnership with patients and families.

Monitoring Protocols for ongoing care:

• Baseline: CBC, CMP, lipids, HbA1c, prolactin, ECG, weight/BMI
• Follow-up: 1, 3, 6, 12 months, then annually
• Clozapine: Weekly CBC × 18 weeks, biweekly × 6 months, then monthly
• Metabolic: Weight at every visit, labs every 3-6 months
• Symptoms: Standardized scales at regular intervals

Treatment Algorithm Essentials:

• First Episode: SGA preferred, lowest effective dose, psychosocial interventions
• Relapse: Assess adherence, optimize dose, consider LAI
• Treatment Resistance: Clozapine after two failed trials
• Comorbidities: Integrated treatment for substance use, depression, anxiety